Immunogenicity, reactogenicity and safety of human rotavirus vaccine (RIX4414) in Indian infants

    loading  Checking for direct PDF access through Ovid



This study was undertaken to assess the immunogenicity, reactogenicity and safety of two doses of an oral live-attenuated human rotavirus vaccine, strain RIX4414 (RotarixTM) in an Indian setting.


The seroconversion rate observed one month post-dose 2 in the RIX4414 group 58.3% [95% CI: 48.7; 67.4] was significantly higher when compared to the placebo group 6.3%; [95% CI: 2.5; 12.5]. The reactogenicity and safety profile was similar for both groups.

Patients and methods:

Healthy infants (N = 363), approximately eight weeks of age were enrolled to receive two doses of RIX4414 vaccine (n = 182) or placebo (n = 181) separated by one month. To assess the immune response, blood samples were taken before vaccination and one month post-dose 2 of RIX4414/placebo. Solicited symptoms were collected for eight-days post each dose and safety data was collected throughout the study.


Two doses of RIX4414 (RotarixTM) were immunogenic, had a good safety profile and were well-tolerated when administered to healthy Indian infants.

Clinical trials registration:; NCT00289172; eTrack 103792.

Related Topics

    loading  Loading Related Articles